NMRA Neumora Therapeutics Inc.

Price (delayed)

$1.765

Market cap

$327.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.33

Enterprise value

$233.33M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 52
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 6
Highlights
The company's EPS rose by 17% YoY and by 8% QoQ
The net income is up by 14% year-on-year and by 6% since the previous quarter
Neumora Therapeutics's equity has shrunk by 69% YoY and by 32% QoQ
Neumora Therapeutics's quick ratio has decreased by 45% YoY and by 13% QoQ

Key stats

What are the main financial stats of NMRA

NMRA stock price

How has the Neumora Therapeutics stock price performed over time
Intraday
1.44%
1 week
-6.12%
1 month
-23.59%
1 year
123.42%
YTD
-1.4%
QTD
-9.49%

Financial performance

How have Neumora Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$223.08M
Net income
-$222.39M
Gross margin
N/A
Net margin
N/A
Neumora Therapeutics's operating income has increased by 19% YoY and by 7% QoQ
The net income is up by 14% year-on-year and by 6% since the previous quarter

Price vs fundamentals

How does NMRA's price correlate with its fundamentals

Growth

What is Neumora Therapeutics's growth rate over time

Valuation

What is Neumora Therapeutics stock price valuation
P/E
N/A
P/B
4.55
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 17% YoY and by 8% QoQ
Neumora Therapeutics's equity has shrunk by 69% YoY and by 32% QoQ
The stock's P/B is 66% above its last 4 quarters average of 2.7

Efficiency

How efficient is Neumora Therapeutics business performance
NMRA's return on invested capital has dropped by 120% year-on-year and by 26% since the previous quarter
The ROE has plunged by 114% YoY and by 24% from the previous quarter
The ROA has plunged by 54% YoY and by 7% from the previous quarter

Dividends

What is NMRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NMRA.

Financial health

How did Neumora Therapeutics financials performed over time
The company's total assets is 85% higher than its total liabilities
The company's total liabilities has surged by 193% YoY but it fell by 4.6% QoQ
Neumora Therapeutics's quick ratio has decreased by 45% YoY and by 13% QoQ
The debt is 24% less than the equity
Neumora Therapeutics's equity has shrunk by 69% YoY and by 32% QoQ
Neumora Therapeutics's debt to equity has increased by 43% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.